Regeneron Pharmaceuticals — Apr 29, 2025 release

net sales decreased 26% to $1.04 billion • Dupixent approved for chronic spontaneous urticaria (CSU) in U.S.; approved for chronic obstructive pulmonary disease (COPD) in Japan • FDA accepted for priority review EYLEA HD sBLA for both retinal vein occlusion (RVO) and for monthly dosing in approved indications; update provided on FDA review of EYLEA HD pre-filled syringe submission • Lynozyfic ™ (linvoseltamab) approved in EU for relapsed/refractory multiple myeloma • Regulatory applications submitted for Libtayo ® in adjuvant cutaneous squamous cell carcinoma (CSCC) in U.S. and EU • Announced ongoing and planned investments in New York and North Carolina infrastructure and manufacturing expected to total more than $7 billion Tarrytown, New York (April 29, 2025) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced financial results for the first quarter of 2025 and provided a business update. "Regeneron has one of the most exciting pipelines in the industry, with unmatched diversity, scientific distinction, and potential to help millions of patients," said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. "We are laser focused on fulfilling the promise of this pipeline by advancing our clinical programs, and expect several important data readouts this year. We are also working to ensure our four blockbuster medicines reach even more patients who could benefit, with year-to-date progress including regulatory approvals for Dupixent in CSU in the U.S. and COPD in Japan." Financial Highlights ($ in millions, except per share data) Q1 2025 Q1 2024 % Change Total revenues $ 3,029  $ 3,145  (4  %) GAAP net income $ 809  $ 722  12  % GAAP net income per share - diluted $ 7.27  $ 6.27  16  % Non-GAAP net income (a) $ 928  $ 1,116  (17  %) Non-GAAP net income per share - diluted (a) $ 8.22  $ 9.55  (14  %) 1 "We have made meaningful progress acro